216 related articles for article (PubMed ID: 22967076)
21. Returning to the stem state: epigenetics of recapitulating pre-differentiation chromatin structure.
Shafa M; Krawetz R; Rancourt DE
Bioessays; 2010 Sep; 32(9):791-9. PubMed ID: 20652894
[TBL] [Abstract][Full Text] [Related]
22. Generation of iPSCs from genetically corrected Brca2 hypomorphic cells: implications in cell reprogramming and stem cell therapy.
Navarro S; Moleiro V; Molina-Estevez FJ; Lozano ML; Chinchon R; Almarza E; Quintana-Bustamante O; Mostoslavsky G; Maetzig T; Galla M; Heinz N; Schiedlmeier B; Torres Y; Modlich U; Samper E; Río P; Segovia JC; Raya A; Güenechea G; Izpisua-Belmonte JC; Bueren JA
Stem Cells; 2014 Feb; 32(2):436-46. PubMed ID: 24420904
[TBL] [Abstract][Full Text] [Related]
23. Concise review: non-cell autonomous reprogramming: a nucleic acid-free approach to induction of pluripotency.
Parameswaran S; Balasubramanian S; Rao MS; Ahmad I
Stem Cells; 2011 Jul; 29(7):1013-20. PubMed ID: 21544901
[TBL] [Abstract][Full Text] [Related]
24. Dedifferentiation, transdifferentiation, and reprogramming: future directions in regenerative medicine.
Eguizabal C; Montserrat N; Veiga A; Izpisua Belmonte JC
Semin Reprod Med; 2013 Jan; 31(1):82-94. PubMed ID: 23329641
[TBL] [Abstract][Full Text] [Related]
25. An orthogonal comparison of the proteome of human embryonic stem cells with that of human induced pluripotent stem cells of different genetic background.
Faradonbeh MZ; Gharechahi J; Mollamohammadi S; Pakzad M; Taei A; Rassouli H; Baharvand H; Salekdeh GH
Mol Biosyst; 2012 Jun; 8(6):1833-40. PubMed ID: 22543856
[TBL] [Abstract][Full Text] [Related]
26. Human induced pluripotent stem cells harbor homoplasmic and heteroplasmic mitochondrial DNA mutations while maintaining human embryonic stem cell-like metabolic reprogramming.
Prigione A; Lichtner B; Kuhl H; Struys EA; Wamelink M; Lehrach H; Ralser M; Timmermann B; Adjaye J
Stem Cells; 2011 Sep; 29(9):1338-48. PubMed ID: 21732474
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial metabolism transition cooperates with nuclear reprogramming during induced pluripotent stem cell generation.
Liu W; Long Q; Chen K; Li S; Xiang G; Chen S; Liu X; Li Y; Yang L; Dong D; Jiang C; Feng Z; Qin D; Liu X
Biochem Biophys Res Commun; 2013 Feb; 431(4):767-71. PubMed ID: 23333381
[TBL] [Abstract][Full Text] [Related]
28. Concise review: harmonies played by microRNAs in cell fate reprogramming.
Moradi S; Asgari S; Baharvand H
Stem Cells; 2014 Jan; 32(1):3-15. PubMed ID: 24155164
[TBL] [Abstract][Full Text] [Related]
29. Induced pluripotent stem cells: current progress and potential for regenerative medicine.
Amabile G; Meissner A
Trends Mol Med; 2009 Feb; 15(2):59-68. PubMed ID: 19162546
[TBL] [Abstract][Full Text] [Related]
30. iPSCs from cancer cells: challenges and opportunities.
Ramos-Mejia V; Fraga MF; Menendez P
Trends Mol Med; 2012 May; 18(5):245-7. PubMed ID: 22521522
[TBL] [Abstract][Full Text] [Related]
31. Comparative analysis of human embryonic stem cell and induced pluripotent stem cell-derived hepatocyte-like cells reveals current drawbacks and possible strategies for improved differentiation.
Jozefczuk J; Prigione A; Chavez L; Adjaye J
Stem Cells Dev; 2011 Jul; 20(7):1259-75. PubMed ID: 21162674
[TBL] [Abstract][Full Text] [Related]
32. Accelerating progress in induced pluripotent stem cell research for neurological diseases.
Ito D; Okano H; Suzuki N
Ann Neurol; 2012 Aug; 72(2):167-74. PubMed ID: 22926850
[TBL] [Abstract][Full Text] [Related]
33. Induced pluripotent stem cells reprogramming: Epigenetics and applications in the regenerative medicine.
Gomes KM; Costa IC; Santos JF; Dourado PM; Forni MF; Ferreira JC
Rev Assoc Med Bras (1992); 2017 Feb; 63(2):180-189. PubMed ID: 28355380
[TBL] [Abstract][Full Text] [Related]
34. Concise review: induced pluripotent stem cells and lineage reprogramming: prospects for bone regeneration.
Illich DJ; Demir N; Stojković M; Scheer M; Rothamel D; Neugebauer J; Hescheler J; Zöller JE
Stem Cells; 2011 Apr; 29(4):555-63. PubMed ID: 21308867
[TBL] [Abstract][Full Text] [Related]
35. Reprogram or reboot: small molecule approaches for the production of induced pluripotent stem cells and direct cell reprogramming.
Jung DW; Kim WH; Williams DR
ACS Chem Biol; 2014 Jan; 9(1):80-95. PubMed ID: 24245936
[TBL] [Abstract][Full Text] [Related]
36. DNA methylation dynamics in human induced pluripotent stem cells.
Nishino K; Umezawa A
Hum Cell; 2016 Jul; 29(3):97-100. PubMed ID: 27083573
[TBL] [Abstract][Full Text] [Related]
37. [Induced pluripotent stem cells: a new paradigm to study human tissues].
Sansac C; Assou S; Bouckenheimer J; Lemaître JM; De Vos J
Biol Aujourdhui; 2016; 210(1):1-8. PubMed ID: 27286575
[TBL] [Abstract][Full Text] [Related]
38. Is aging a barrier to reprogramming? Lessons from induced pluripotent stem cells.
Phanthong P; Raveh-Amit H; Li T; Kitiyanant Y; Dinnyes A
Biogerontology; 2013 Dec; 14(6):591-602. PubMed ID: 23963527
[TBL] [Abstract][Full Text] [Related]
39. Nonviral delivery for reprogramming to pluripotency and differentiation.
Park HJ; Shin J; Kim J; Cho SW
Arch Pharm Res; 2014 Jan; 37(1):107-19. PubMed ID: 24222505
[TBL] [Abstract][Full Text] [Related]
40. Proteomic analysis of cell fate decision.
Hansson J; Krijgsveld J
Curr Opin Genet Dev; 2013 Oct; 23(5):540-7. PubMed ID: 23942315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
